Message from the Guest Editor

In the last decade we have gained a deeper understanding of the underlying pathogenesis of various ocular disease, which has resulted in the development of novel effective targeted therapies such as teprotumumab for the treatment of active thyroid eye disease.

This Special Issue of *Journal of Personalized Medicine* aims to update the current evidence and collect the latest findings on various ocular disease.

Particular attention will be paid to original research articles, case reports, and state-of-the-art reviews to explore how to overcome the challenges and navigate the emerging therapeutic landscape.
Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com
jpm@mdpi.com
@JPM_MDPI